Published in Exp Biol Med (Maywood) on January 01, 2017
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol (2008) 5.50
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng (2012) 4.31
Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med (2012) 3.61
Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev (2010) 3.30
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood (2003) 3.25
Structure of tobacco mosaic virus at 3.6 A resolution: implications for assembly. Science (1986) 2.77
Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol (2003) 2.75
Dual-surface modification of the tobacco mosaic virus. J Am Chem Soc (2005) 1.86
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release (2008) 1.59
Surface modification of tobacco mosaic virus with "click" chemistry. Chembiochem (2008) 1.43
The art of engineering viral nanoparticles. Mol Pharm (2010) 1.30
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood (2009) 1.19
Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B Mater Biol Med (2013) 1.10
TMV nanorods with programmed longitudinal domains of differently addressable coat proteins. Nanoscale (2013) 1.01
The Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter Nanorods. Adv Healthc Mater (2015) 1.01
Antibody-drug conjugates—a new wave of cancer drugs. Bioorg Med Chem Lett (2014) 1.00
Current methods for the synthesis of homogeneous antibody-drug conjugates. Biotechnol Adv (2015) 0.95
Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther (2008) 0.95
Antibody-cytotoxic agent conjugates for cancer therapy. Expert Opin Drug Deliv (2005) 0.93
The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol (2011) 0.88
Interface of physics and biology: engineering virus-based nanoparticles for biophotonics. Bioconjug Chem (2015) 0.88
Bottom-up-assembled nanostar colloids of gold cores and tubes derived from tobacco mosaic virus. Angew Chem Int Ed Engl (2013) 0.88
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res (2016) 0.87
Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy. ACS Nano (2016) 0.82
Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer. J Control Release (2016) 0.81
Stable Disk Assemblies of a Tobacco Mosaic Virus Mutant as Nanoscale Scaffolds for Applications in Drug Delivery. Bioconjug Chem (2016) 0.80
Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays. Sci Rep (2016) 0.78
High Aspect Ratio Nanotubes Formed by Tobacco Mosaic Virus for Delivery of Photodynamic Agents Targeting Melanoma. ACS Biomater Sci Eng (2016) 0.77
Size Dependent Cellular Uptake of Rod-like Bionanoparticles with Different Aspect Ratios. Sci Rep (2016) 0.76